Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia

Table 2 Preoperative Demographics

Demographics	Non-TXA Group (N = 18)	TXA Group (N = 16)	p Value
Duration of surgery (min)^a	89.1 ± 30.1	87.4 ± 30.4	0.873
Total blood loss (mL)^a	1464 ± 480	935 ± 394	0.001
Intraoperative blood loss (mL)^a	397 ± 183	264 ± 69	0.009
Drainage volume (mL)^a	354 ± 119	236 ± 91	0.003
Hidden blood loss (mL)^a	713 ± 474	435 ± 277	0.043
Amount of FVIII usage (IU)^a	42,125 ± 1965	36,328 ± 4858	< 0.001
Transfusion rate (%)^b	61%	19%	0.017
Transfusion amount (RBC suspension) per patient (mL)^a	178 ± 166	38 ± 81	0.004
Transfusion amount (plasma) per patient (mL)^a	56 ± 92	13 ± 50	0.106
Swelling ratio (Knee) (%)^a
POD1	113.0 ± 3.8	107.0 ± 3.5	0.001
POD2	116.2 ± 4.7	108.8 ± 3.6	< 0.001
POD3	116.9 ± 4.9	109.5 ± 3.4	< 0.001
POD5	116.2 ± 4.2	106.6 ± 2.8	< 0.001
Swelling ratio (Hip) (%)^a
POD1	115.6 ± 6.4	111.0 ± 4.8	0.099
POD2	118.7 ± 3.6	113.1 ± 4.4	0.012
POD3	118.1 ± 4.3	113.8 ± 4.6	0.058
POD5	115.1 ± 4.3	110.1 ± 2.9	0.010
Maximum Hb change (g/L)^a	32 ± 6	22 ± 7	< 0.001
Length of hospital stay^a	20 ± 6	14 ± 4	< 0.001

Abbreviations: TXA tranexamic acid; RBC red blood cell; POD1 postoperative day 1; POD2 postoperative day 2; POD3 postoperative day 3; postoperative day 5; Hb hemoglobin
^a The values are given as mean ± standard deviation
^b The values are given a percentage

ISSN: 1471-2474